ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024
Long-Term Nephrotoxicity of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 53 citations in OpenAlex.
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Theranostic Potential ofCancers · 2026Article
- Quantifying the Renal Impact of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [European journal of nuclear medicine and molecular imaging · 2026Article
- Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Could we reduce renal toxicity of [European journal of nuclear medicine and molecular imaging · 2026Article
- The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.The oncologist · 2026Review
- PET-based risk stratification for adverse events under [European journal of nuclear medicine and molecular imaging · 2026Article
- [Wiener klinische Wochenschrift · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Zwitterionic Modification of PSMA Ligands Reduces Off-Target Binding and Tissue Retention.Journal of medicinal chemistry · 2026Article
- Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Estimation of split renal function using [EJNMMI research · 2026Article
- Radioligand treatment with [European journal of nuclear medicine and molecular imaging · 2026Article
- Current and future perspectives on radioligand therapy in advanced prostate cancer.Therapeutic advances in medical oncology · 2026Review
- Frailty and [Theranostics · 2026Review
Corrections and comments
- Commented on by
- Erratum issuedErrata.2024
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-emitting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.